|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.22 USD | +1.65% |
|
-1.44% | -29.06% |
| 03:18pm | UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating | MT |
| 11-13 | Genscript Bio Associate Legend Biotech's Loss Doubles in Q3 | MT |
| Capitalization | 7.62B 7.21B 6.68B 5.98B 10.77B 645B 11.93B 83.18B 30.75B 265B 28.63B 27.99B 1,143B | P/E ratio 2024 * |
-32.4x | P/E ratio 2025 * | -39x |
|---|---|---|---|---|---|
| Enterprise value | 6.77B 6.41B 5.94B 5.31B 9.58B 574B 10.6B 73.95B 27.34B 236B 25.45B 24.88B 1,016B | EV / Sales 2024 * |
10.9x | EV / Sales 2025 * | 6.72x |
| Free-Float |
-
| Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | +1.70% | ||
| 1 week | -1.44% | ||
| Current month | +1.46% | ||
| 1 month | +6.61% | ||
| 3 months | -15.24% | ||
| 6 months | -6.27% | ||
| Current year | -29.06% |
1 week
40.97
44.56
1 month
36.9244.56
Current year
36.9270.13
1 year
36.9270.13
3 years
30.7677.32
5 years
23.4177.32
10 years
23.4177.32
| Director | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 20/09/2020 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 08/05/2022 |
Mythili Koneru
CTO | Chief Tech/Sci/R&D Officer | 46 | 10/04/2023 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ye Wang
CHM | Chairman | 55 | 05/11/2020 |
Ying Huang
BRD | Director/Board Member | 51 | 29/12/2021 |
Corazon Sanders
BRD | Director/Board Member | 67 | 30/04/2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 1 M€ | -20.08% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.65% | -1.44% | -28.85% | -16.73% | 7.62B | ||
| +1.96% | +0.94% | +31.95% | +125.57% | 119B | ||
| +1.70% | +4.61% | -5.95% | +19.86% | 83.7B | ||
| -0.95% | -0.78% | +40.03% | +116.18% | 37.69B | ||
| -2.02% | +1.88% | +18.82% | -57.99% | 29.18B | ||
| +0.09% | -0.56% | +17.22% | -33.05% | 21.85B | ||
| +6.81% | +17.63% | -22.39% | -57.72% | 21.71B | ||
| +0.81% | +0.64% | -29.34% | -40.87% | 14.53B | ||
| +0.13% | +0.22% | +782.38% | +278.16% | 13.67B | ||
| -3.28% | +0.36% | +166.62% | +169.99% | 13.49B | ||
| Average | +0.67% | +1.53% | +97.05% | +50.34% | 36.25B | |
| Weighted average by Cap. | +1.13% | +1.30% | +48.42% | +62.61% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 620M 587M 544M 487M 877M 52.54B 971M 6.77B 2.5B 21.59B 2.33B 2.28B 93.01B | 1.02B 968M 897M 802M 1.45B 86.61B 1.6B 11.16B 4.13B 35.58B 3.84B 3.76B 153B |
| Net income | -243M -230M -213M -191M -343M -20.57B -380M -2.65B -980M -8.45B -913M -892M -36.42B | -115M -109M -101M -90.03M -162M -9.72B -180M -1.25B -463M -3.99B -431M -422M -17.2B |
| Net Debt | -846M -801M -742M -664M -1.2B -71.64B -1.32B -9.23B -3.41B -29.44B -3.18B -3.11B -127B | -744M -704M -652M -583M -1.05B -62.98B -1.16B -8.12B -3B -25.88B -2.79B -2.73B -111B |
More financial data
* Estimated data
Employees
2,400
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/24 | 42.61 $ | +2.58% | 407,949 |
| 06/12/24 | 41.54 $ | -0.29% | 1,318,303 |
| 05/12/24 | 41.66 $ | -1.86% | 1,153,551 |
| 04/12/24 | 42.45 $ | -2.82% | 1,074,977 |
| 03/12/24 | 43.68 $ | +0.85% | 1,083,453 |
Delayed Quote Nasdaq, December 09, 2024 at 04:20 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
41.54USD
Average target price
82.00USD
Spread / Average Target
+97.40%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LEGN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition